@article {Yanover2020.05.07.20091652, author = {Chen Yanover and Barak Mizrahi and Nir Kalkstein and Karni Marcus and Pinchas Akiva and Yael Barer and Varda Shalev and Gabriel Chodick}, title = {What factors increase the risk of complications in SARS-CoV-2 positive patients? A cohort study in a nationwide Israeli health organization}, elocation-id = {2020.05.07.20091652}, year = {2020}, doi = {10.1101/2020.05.07.20091652}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Reliably identifying patients at increased risk for COVID-19 complications could guide clinical decisions, public health policies, and preparedness efforts. To date, the most globally accepted definitions of at-risk patients rely, primarily, on epidemiological characterization of hospitalized COVID-19 patients. However, such characterization overlooks, and fails to correct for, the prevalence of existing conditions in the wider SARS-CoV-2 positive population. Here, we analyze the complete medical records of all SARS-CoV-2 infected individuals (N=4,353) in a large Israeli health organization (representing a population of 2.3 million people), of whom 173 experienced moderate or severe symptoms of COVID-19, to identify the conditions that increase the risk of disease complications, in various age and sex strata. Our analysis suggests that cardiovascular and kidney diseases, obesity, and hypertension are significant risk factors for COVID-19 complications, as previously reported. Interestingly, it also indicates that depression (e.g., odds ratio, OR, for males 65 years or older: 2.94, 95\% confidence intervals [1.55, 5.58]; P-value = 0.014) as well cognitive and neurological disorder (e.g., OR for individuals >= 65 year old: 2.65 [1.69, 4.17]; P-value \< 0.001) are significant risk factors; and that smoking and background of respiratory diseases do not significantly increase the risk of complications. Adjusting existing risk definitions following these observations may improve their accuracy and impact the global pandemic containment efforts.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form, with the following declarations made: PA reports personal fees and other from Medial Research, outside the submitted work.Funding StatementNo external funding was received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPatient-level de-identified data from Maccabi Health Services}, URL = {https://www.medrxiv.org/content/early/2020/05/13/2020.05.07.20091652}, eprint = {https://www.medrxiv.org/content/early/2020/05/13/2020.05.07.20091652.full.pdf}, journal = {medRxiv} }